Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Apatinib Neoadjuvant Therapy for Resectable NSCLC
NCT07031154Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Xiamen University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07031154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07031154.